Contentious Ketek correspondence
Executive Summary
CDER officials reiterate that they did not rely on a fraudulent study to approve Sanofi-Aventis' antibiotic Ketek (telithromycin), in a letter in the April 19 New England Journal of Medicine. In response to a critical perspective article by former FDA reviewer David Ross, the FDAers say they "reviewed the study for safety findings that would have counted 'against the drug,' as is consistent with good review practice," and that data-integrity issues with study 3014 were not provided to an advisory committee so as not to compromise an on-going investigation. Not addressed by the response are Ross' charges that Ketek reviewers were subject to "overt internal pressure ... to alter their conclusions." Ketek's approval is being investigated by the House Energy and Commerce/Oversight and Investigations Subcommittee (1"The Pink Sheet" April 9, 2007, In Brief)...
You may also be interested in...
Ketek subpoenas
Frustrated by FDA foot-dragging, House Energy and Commerce Oversight Subcommittee members vote 12-0, Jan. 31, to compel testimony from three FDA criminal investigators and a clinical research assistant involved with a controversial safety study for Sanofi-Aventis' Ketek (telithromycin). The four are expected to testify Feb. 12 as the panel continues its bipartisan probe into how FDA officials reviewed the ketolide antibiotic (1"The Pink Sheet" April 23, 2007, In Brief). A briefing book and documents used to prepare FDA Commissioner Andrew von Eschenbach for a March 22, 2007 hearing on Ketek also is the subject of a subpoena...
FDA commissioner not a star witness
The "accuracy and candor" of statements by FDA Commissioner Andrew von Eschenbach at recent House Energy and Commerce/Oversight and Investigations Subcommittee hearings concerning approval of Sanofi Aventis's Ketek are being scrutinized by the panel. In a letter to HHS Secretary Michael Leavitt, full committee chairman John Dingell, D-Mich., and subcommittee head Bart Stupak, D-Mich., request all briefing materials and communications related to von Eschenbach's remarks, as well as interviews with agency staff who helped prepare the testimony. The records were due by April 4, but the committee said it had not received an "adequate response"...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”